Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib in Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT05276063Phase 3Completed
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of linsitinib in thyroid eye disease (TED), sponsored by Sling Therapeutics, Inc.. Started Jul 2022; status: completed.
02
Drugs
linsitinib
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05276063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276063.